Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma

por Prado, C M M, Bekaii-Saab, T, Doyle, L A, Shrestha, S, Ghosh, S, Baracos, V E, Sawyer, M B
Publicado 2012

Expression of a 95 kDa membrane protein is associated with low daunorubicin accumulation in leukaemic blast cells.

por Doyle, L. A., Ross, D. D., Sridhara, R., Fojo, A. T., Kaufmann, S. H., Lee, E. J., Schiffer, C. A.
Publicado 1995

An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein.

por Doyle, L. A., Ross, D. D., Ordonez, J. V., Yang, W., Gao, Y., Tong, Y., Belani, C. P., Gutheil, J. C.
Publicado 1995

Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma

por Naing, A, LoRusso, P, Fu, S, Hong, D, Chen, H X, Doyle, L A, Phan, A T, Habra, M A, Kurzrock, R
Publicado 2013

A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours

por Wilky, B A, Rudek, M A, Ahmed, S, Laheru, D A, Cosgrove, D, Donehower, R C, Nelkin, B, Ball, D, Doyle, L A, Chen, H, Ye, X, Bigley, G, Womack, C, Azad, N S
Publicado 2015

Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors

por Koczywas, M, Frankel, P H, Synold, T W, Lenz, H-J, Mortimer, J E, El-Khoueiry, A B, Gandara, D R, Cristea, M C, Chung, V M, Lim, D, Reckamp, K L, Lau, D H, Doyle, L A, Ruel, C, Carroll, M I, Newman, E M
Publicado 2014